Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$166,000Cash on Hand
0.3mo Cash Runway
Follow NRSN by emailGet an email when NRSN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NRSN, unsubscribe in one click. Privacy
📣 What NRSN Says Is Next
Q1 2027 · “Decision on non-dilutive grant funding for Phase 3 PARAGON: expected in Q1 2027, subject to completion of the ongoing grant review.”
Company press release, Oct 13, 2026 · SEC filing
coming months · “NeuroSense expects to complete and file the submission in the coming months.”
Company press release, Jul 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 2, 2026 ·
Regulatory Plans to add new neurofilament light chain (NfL) data to the Health Canada New Drug Submission for PrimeC in ALS, with filing now targeted for March 2027 instead of December 2026. In the new analysis, PrimeC-treated participants showed a greater NfL reduction than placebo. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Deal Signed a strategic collaboration agreement with an advisor to supply PrimeC, its ALS candidate, to eligible patients through a licensed U.S. clinical treatment center, targeting first revenues in the first half of 2027. Form 6-K · SEC filing
Oct 19, 2026 ·
NeuroSense filed a U.S. patent application covering use of PrimeC, a ciprofloxacin and celecoxib combination, for traumatic brain injury including concussion, blast injury and CTE. Form 6-K · SEC filing · Press release
Oct 13, 2026 ·
Listing NeuroSense has a Nasdaq Hearings Panel hearing scheduled for November 10, 2026, after appealing an October 1 delisting determination. Its shares continue trading pending the decision. The $1.00 minimum bid price deficiency is cured, but the $35 million market value of listed securities requirement remains unmet. Form 6-K · SEC filing · Press release
Oct 2, 2026 ·
Listing NeuroSense received a Nasdaq Staff Determination on October 1, 2026 saying it has not regained the $35 million minimum market value of listed securities, and it plans to request a Panel hearing seeking up to 180 more days. It also regained compliance with the $1.00 minimum bid price after a 1-for-20 reverse split. Form 6-K · SEC filing · Press release
Sep 25, 2026 ·
Earnings NeuroSense reported H1 2026 R&D expenses of $2,102 thousand versus $2,503 thousand a year earlier, and G&A of $1,345 thousand versus $2,189 thousand. Cash was $231 thousand at June 30, 2026, and shareholders' deficit was $2,103 thousand. It targets a December 2026 NDS filing in Canada for PrimeC in ALS. Form 6-K · SEC filing · Press release
Sep 9, 2026 ·
Listing NeuroSense will effect a 1-for-20 reverse share split, with shares trading on a split-adjusted basis on Nasdaq Capital Market starting September 14, 2026. Outstanding shares fall from 37,938,036 to 1,896,902, and fractional shares will be rounded up. Form 6-K · SEC filing
Aug 27, 2026 ·
Shareholder vote Shareholders approved at an August 26, 2026 special meeting giving the Board discretion to effect one or more reverse share splits at an aggregate ratio from 1-for-4 to 1-for-40, with the exact ratio and timing to be set within 12 months. No amendment to the Articles of Association would be required. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2023 · Phase 2 · Results Expected · A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS Registry primary completion date, not a results date
Aug 2022 · Phase 1 · Results Expected · A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject Registry primary completion date, not a results date
Apr 2022 · Phase 1 · Results Expected · A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects Registry primary completion date, not a results date
Sep 2021 · Phase 1 · Results Expected · Ciprofloxacin/Celecoxib Combination in Patients With ALS Registry primary completion date, not a results date
Jan 2021 · Phase 2 · Results Expected · Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not NRSN's own candidates): Celecoxib, Ciprofloxacin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NRSN holds $166,000 in cash and short-term investments and burns about $1.9M/quarter from operations,
an estimated runway of 0.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:79 · High
Cash runway 0 months +40
ATM program on file since Jan 2026 +15
Shelf registration (F-3, Jan 2026) +10
Share count +40% in a year +14
Recent financing filings on SEC EDGAR:
Jan 29, 2026 · Shelf registration with ATM program, up to $7M · F-3
Share count 32,557,174 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NRSN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NRSN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.